How to invest in uranium as nuclear power returns
Nuclear power is back on the agenda after a decade in the doldrums. Fuel prices will be volatile, but the long-term path should be up
Nuclear power is back in the headlines. Unrest in Kazakhstan, which provides over 40% of the world’s uranium (the fuel most widely used to power nuclear plants), sent spot prices for the metal up nearly 10% to $46 per pound on 5 January. Uranium equities traded up 5%-10% on the possibility of supply disruption.
A potentially more important story got less media coverage. The European Union has said that it intends to allow nuclear-energy projects to be classified as sustainable investments. This could be very positive for demand and long-term prices – although investing in uranium is likely to be a roller-coaster ride and not for the faint-hearted.
A lost decade ends
The 2010s were a desperate decade for uranium. Back in June 2007, prices hit $136 for spot prices and $95 for long-term contracts. They then headed down to a low in October 2016 of $18.75 for spot prices and $35.50 for long-term contracts (you can find this data on the website of Cameco, one of the biggest miners.)
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The major reason was that nuclear fell from favour after the Fukushima disaster. Both Japan and Germany ditched their nuclear programmes (although Japan has now stopped plant closures). Uranium ended up in a severe supply glut, which took many years to reduce through unprecedented mine closures.
However, prices have ticked steadily higher since 2016. The political environment is changing for the better, but there is another force at work. Uranium is being financialised. There are now two funds that buy uranium (specifically, uranium oxide concentrate, known as yellow cake).
The biggest is Sprott Physical Uranium Trust (Toronto: U-UN), created in July when Sprott Asset Management took over an existing fund called Uranium Participation. This has become a market-moving force since Sprott took control. It has more than doubled in size in six months, owns almost 44 million pounds of uranium, and has a market capitalisation of US$2bn. The fund intends to raise up to $3.5bn in capital over two years, of which it had raised $1bn by November. The management cost is 0.35% per year, plus expenses, and the shares are at a 0.5% premium to the latest net asset value (NAV).
Yellow Cake (LSE: YCA) owns 19 million pounds of uranium and has a market cap of £600m, which includes around £170m in capital raised since June. It has an agreement with Kazakhstan’s Kazatomprom giving it the right to buy up to $100m per year of uranium oxide until 2027. Ongoing charges were 0.7% of NAV last year. The share price is at a discount of 10% to the latest NAV (339p) in November.
Both vehicles are a direct play on uranium prices, but also on the dynamics of the market. Utilities buy most uranium on long-term contracts and the difference between spot and contract prices can be substantial. As demand increases, more firms might have to head on to the spot markets – or pay more to secure long-term supplies. An Asian utility is said to be seeking a contract for 2025-2030 with a ceiling price of $78, according to Nick Lawson of asset-raising adviser Ocean Wall – well above current long-term prices of $43.
An even more volatile play
The alternative is to buy a fund that holds uranium miners, such as Geiger Counter (LSE: GCL). This small trust has net assets of £48m. The top four holdings are Nexgen Energy, UR-Energy, IsoEnergy, and Cameco, which account for 42% of the portfolio. The premium to latest NAV is 6% and the management charge last year was 1.38%, plus expenses.
As an investor in mining equities – which are a geared play on the commodities they produce – its shares have been more volatile. Yellow Cake has roughly doubled from its low price in March 2020, but Geiger Counter is up almost fivefold (from 10p to 48p) – yet down 35% from its November high.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Higher rates are disappearing – should you fix your savings?
Fixed savings rates have dropped to their lowest levels in over a year. Should you fix your savings now ahead of a potential base rate cut in November?
By Katie Williams Published
-
Nine million people fall victim to financial scams, says Citizens Advice
The charity says that around one in five people across the UK have been caught out by a finance scam in the past year - here is how to protect your money
By Chris Newlands Published
-
What will a broken-up Google look like?
The US courts have ruled that Google is a monopoly, leaving it facing the prospect of a break-up. WIll that be a good thing?
By Matthew Lynn Published
-
How will the UK gambling sector be hit by the Budget?
There are concerns for the UK gambling sector in the lead-up to the Autumn Budget. What could be on the cards?
By Dr Matthew Partridge Published
-
HSBC returns to cost-cutting plan
HSBC is set to revamp its commercial banking division – but will it come at a cost?
By Dr Matthew Partridge Published
-
Pfizer shares rise as US investor takes $1 billion stake
Pfizer shares are on the up since US activist investor Starboard Value built up a stake in the drug maker. But strategic options appear limited
By Dr Matthew Partridge Published
-
Qualcomm could acquire rival Intel – but securing the deal won't be easy
A tie-up between Qualcomm and its semiconductor rival Intel would be a coup. But multiple regulatory and commercial hurdles lie ahead.
By Dr Matthew Partridge Published
-
How to invest in the quiet market months
Here's how to invest in the quiet market months, since “sell in May” hasn’t paid off this year.
By Cris Sholto Heaton Published
-
Spire Healthcare: invest in the booming demand for private healthcare
Spire Healthcare is one of the few listed companies benefiting from the growing trend in private healthcare. Should you invest?
By Rupert Hargreaves Published
-
Are insurance companies a good investment?
Costs may be soaring but the insurance sector is currently going through one of its most profitable periods. The market has been slow to realise the opportunity here
By Rupert Hargreaves Published